CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 59 enrolled
Drug / intervention
recombinant adenovirus-p53 SCH-58500biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00002960
NCT00002960Phase 1Completed
CompareCT.gov

A Phase I Study in Patients With Peritoneal Carcinomatosis Using SCH 58500 (rAd/p53) Administered by Single Intraperitoneal Instillation

Merck Sharp & Dohme LLC·interventional·Posted Aug 24, 2004·Updated Feb 4, 2016

In Brief

A Phase 1 clinical trial evaluating recombinant adenovirus-p53 SCH-58500 for Fallopian Tube Cancer and 3 related conditions. Completed, enrolled 59 participants.

Detailed Summary

RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SCH-58500 in treating patients who have recurrent or persistent primary ovarian, fallopian tube, or peritoneal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 24, 2004
Enrollment StartJun 1, 1999
Primary CompletionJul 1, 2000
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 21.9 years ago

Interventions

recombinant adenovirus-p53 SCH-58500biological